Related Experiment Video
Updated: Dec 26, 2025
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model
Byung-Hak Kim1,2,3, Haeri Lee1,2, Cheol Gyu Park4
1Department of Pharmacology, Seoul National University College of Medicine, Seoul 03080, Korea.
Abstract:
Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for cancer therapy. We recently identified ODZ10117 as a small molecule inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted cancer therapy. Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells. In addition, ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs). Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells. Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3.
Insights
ODZ10117 effectively targets Signal Transducer and Activator of Transcription 3 (STAT3) in glioblastoma. This novel small molecule inhibitor demonstrates therapeutic efficacy by reducing tumor cell invasion and promoting cell death, offering a promising treatment avenue.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Constitutively activated Signal Transducer and Activator of Transcription 3 (STAT3) is crucial in cancer development, progression, and drug resistance, particularly in glioblastoma.
- STAT3 represents a significant therapeutic target for various cancers.
Purpose of the Study:
- To evaluate the therapeutic efficacy of ODZ10117, a novel small molecule STAT3 inhibitor, in glioblastoma models.
- To investigate the mechanisms by which ODZ10117 exerts its anti-cancer effects in glioblastoma.
Main Methods:
- In vitro studies using glioblastoma cell lines and patient-derived primary glioblastoma cells.
- Assessment of cell migration, invasion, apoptosis, and stem cell properties.
- In vivo studies using mouse xenograft models of glioblastoma and glioma stem cells (GSCs).
Main Results:
- ODZ10117 significantly inhibited migration and invasion of glioblastoma cells.
- ODZ10117 induced apoptotic cell death in glioblastoma cells.
- ODZ10117 suppressed stem cell properties in GSCs.
- ODZ10117 demonstrated significant therapeutic efficacy in preclinical glioblastoma xenograft models.
Conclusions:
- ODZ10117 is a potent therapeutic candidate for glioblastoma treatment by targeting STAT3.
- ODZ10117 exhibits anti-migratory, anti-invasive, and pro-apoptotic effects.
- ODZ10117 effectively targets GSCs and shows promise in vivo.
